Vectored immunoprophylaxis and treatment of SARS-CoV-2 infection in a preclinical model.

Vectored immunoprophylaxis was first developed as a means of establishing engineered immunity to HIV using an adenoassociated viral vector expressing a broadly neutralizing antibody. We applied this concept to establish long-term prophylaxis against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a mouse model using adenoassociated virus and lentiviral vectors expressing a high-affinity angiotensin-converting enzyme 2 (ACE2) decoy. Administration of decoy-expressing (adenoassociated virus) AAV2.retro and AAV6.2 vectors by intranasal instillation or intramuscular injection protected mice against high-titered SARS-CoV-2 infection. AAV and lentiviral vectored immunoprophylaxis was durable and was active against SARS-CoV-2 Omicron subvariants. The AAV vectors were also effective therapeutically when administered postinfection. Vectored immunoprophylaxis could be of value for immunocompromised individuals for whom vaccination is not practical and as a means to rapidly establish protection from infection. Unlike monoclonal antibody therapy, the approach is expected to remain active despite continued evolution viral variants.

Prevention of COVID-19 coronavirus infection with aminodihydrophthalazinedione sodium (Galavit) in medical staff of the "red zone": results of the multicenter observational study

COVID-hospital healthcare workers belong to a high-risk SARS-CoV-2 infection. The aminodihydrophthalazinedione sodium (Galavit) belongs to the group of immunomodulatory and anti-inflammatory drugs. It has been shown that aminodihydrophthalazinedione sodium is effective in the prevention of acute respiratory infections, respiratory tract diseases and ENT-organs of bacterial and viral etiology. The purpose of the study. To evaluate the effectiveness and safety of immunoprophylaxis of new coronavirus infection (COVID-19) with aminodihydrophthalazinedione sodium in healthcare workers providing medical care in the "red zone". Material and methods. A multicenter prospective-retrospective observational comparative non-randomized study in healthcare workers providing medical care in the "red zone" was conducted. 428 participants were included in the study: the observation group - healthcare workers who administered aminodihydrophthalazinedione sodium (Galavit) for prophylactic purposes (n=214), and control group (n=214). The observation period of the participants or the period of collecting retrospective data in the study was 30 days. The results of PCR tests and tests for antibodies to the SARS-CoV-2 were analyzed, clinical status (COVID-19 in any form) was assessed. Descriptive statistic methods and Pearson chi2 test were used. The risk ratios, odds ratios and 95% confidence intervals were calculated with them. The influence of potential confounding factors (age, gender, work place in clinical site, the presence or absence of concomitant disease) on the clinical status were analyzed using logistic regression. The analysis of propensity score matching was carried out. The Stata/IC 14.2 for Windows software used for statistical analysis. Results and discussion. Observational study results describe the risk ratios and odds ratios of infection with a new coronavirus (COVID-19) in healthcare workers providing medical care in the "red zone" considering prophylactic administration of aminodihydrophthalazinedione sodium (Galavit). 205 (95.8%) participants in the group of healthcare workers who took aminodihydrophthalazinedione sodium (Galavit) for prophylactic purposes and 194 (90.7%) participants in control group had a negative PCR test during the observation period, chi2=4.48, p=0.034. The risk of a positive status according to the PCR test for 30 days in the preventive group was 0,04, and in the control group 0.09. The risk difference was -0.05 [95% confidence interval (CI) -0.099;-0.004]. The adjusted odds ratio using multiple logistic regression was - 0.41 (95% CI 0.18-0.93). No adverse events were observed during the prophylactic administration of aminodihydrophthalazinedione sodium over 30 days. Conclusion. Galavit preventive administration in a tablet form at a dose of 50-100 mg per day by employees of medical institutions providing medical care to patients with CIVID-19 significantly reduces the risk of SARS-CoV-2 infection and more than 2 times increases the chances not ill of new coronavirus infection. Galavit administration up to 30 days at a dose of 50-100 mg was well tolerated, no adverse events were registered.Copyright © 2022 by the authors.

Approaches to vaccination against coronavirus infection in patients with autoimmune inflammatory rheumatic diseases

The problem of COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases is discussed. There is an increased risk of viral infections in these patients. Attending physicians should provide patients with rheumatic diseases with complete information about the risks and benefits of COVID-19 immunoprophylaxis. The use of immunosuppressive drugs, rather than the diseases themselves, can reduce the level of post-vaccination immune response. This requires choosing the optimal time for carrying out COVID-19 vaccination in this group of patients. Fragments of European and American recommendations on vaccination against COVID-19 in patients with rheumatic diseases are given.Copyright © 2022 Infectious Diseases: News, Opinions, Training.

Versatile Use of Mycobacterium indicus pranii (MIP) Vaccine

Mycobacterium indicus pranii (MIP) earlier known as Mw is a soil-borne, non-pathogenic, saprophytic and rapidly growing strain of mycobacteria. MIP is approved as a vaccine/ immunomodulator for various indications including mycobacterium infections like leprosy in humans. Its administration has resulted in satisfactory clinical improvement, accelerated bacillary clearance, and increased immune responses to Mycobacterium leprae antigens, thereby shortening the full recovery time of the patients. It also shares its antigens with M.tuberculosis. In the last decade, RCTs have been done establishing immunotherapeutic properties of MIP in the treatment of leprosy, tuberculosis, warts and experimently in leishmaniasis. Through its immune inducing and cytotoxic property, it has also proved beneficial for human use especially in treating lung cancer. The beneficial role of it is also being explored in breast, cervical, oral, liver, and bladder cancers. Various studies on MIP have shown that it has immune-modulating properties in humans. The curiosity of the human mind has led to it being tried in Covid treatment trials. The results have shown that administering MIP has lowered inflammatory markers in Covid 19 patients, promising us for it to be a potential treatment option. More RCTs with a larger sample size should be done to establish this. Cytokine storm seen in bacterial sepsis is also decreased with MIP administration. Considering the encouraging results in hastening recovery in various diseases it appears that MIP is perhaps not being exploited to its fullest potential. © 2023, Hind Kusht Nivaran Sangh (Indian Leprosy Association). All rights reserved.

An experience of scaling and intensifying the industrial production of the Gam-COVID-Vac vector adenovirus vaccine in the limiting conditions of the pandemic.

The COVID-19 pandemic has presented a global challenge to the health system. More than 200 years of world epidemiological experience since the first mass use of vaccines have convincingly shown that effective vaccines are the key tools in the fight against dangerous infectious diseases, especially epidemic and pandemic ones. In the context of a rapidly spreading pandemic of a new infectious agent, it is crucial not only to develop fundamentally new vaccines, but also to be able to quickly organise their large-scale production. In the Russian Federation, in 2020, a team of the National Research Centre for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya developed an innovative vector vaccine, Gam-COVID-Vac, for the prevention of coronavirus disease caused by the SARS-CoV-2 virus. A number of pharmaceutical companies faced the challenge of producing the vaccine. The aim of the study was to optimise the production technology of Gam-COVID-Vac for scaling and increasing the production capacity. In the course of the work, the authors established critical quality attributes of the product, optimised analytical methods for their control, identified poorly scalable technological stages, streamlined the technological process before its transfer to production, and modified non-scalable and technologically unfeasible stages. The work resulted in the launch of industrial-scale production of active pharmaceutical ingredients for both components of Gam-COVID-Vac, which made it possible not only to meet the critical need for COVID-19 immunoprophylaxis in the Russian Federation, but also to supply this vaccine to a number of foreign countries.Copyright © 2023 Safety and Risk of Pharmacotherapy. All rights reserved.

Recent progress in immunoprophylaxis of severe acute respiratory syndrome coronavirus 2 in children younger than 5 years.

Immunoprophylaxis refers to the strategy to enhance specific immunity of the body through artificial methods, which can be divided into active immunization (mainly vaccination) and passive immunization (including maternal vaccination). Vaccination is the most cost - effective measure to prevent and control the novel coronavirus disease 2019 (COVID -19). Recently, the United States, Costa Rica and Australia have authorized use of the COVID - 19 vaccine for children down to 6 months of age. In real - world evaluation, maternal vaccination was associated with a substantial reduction in incidence of severe acute respiratory syndrome coronavirus 2 (SARS - CoV - 2) infection, the risk of COVID - 19 related hospitalization and critical illness among infants younger than 6 months of age. Coupled with these advances in young children, it is possible to achieve the whole population coverage of SARS - CoV - 2 mmune prevention.Copyright © 2022 Chinese Journal of Applied Clinical Pediatrics. All rights reserved.

The Human Nose Organoid Respiratory Virus Model: an Ex Vivo Human Challenge Model To Study Respiratory Syncytial Virus (RSV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pathogenesis and Evaluate Therapeutics.

There is an unmet need for preclinical models to understand the pathogenesis of human respiratory viruses and predict responsiveness to immunotherapies. Airway organoids can serve as an ex vivo human airway model to study respiratory viral pathogenesis; however, they rely on invasive techniques to obtain patient samples. Here, we report a noninvasive technique to generate human nose organoids (HNOs) as an alternative to biopsy-derived organoids. We made air-liquid interface (ALI) cultures from HNOs and assessed infection with two major human respiratory viruses, respiratory syncytial virus (RSV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Infected HNO-ALI cultures recapitulate aspects of RSV and SARS-CoV-2 infection, including viral shedding, ciliary damage, innate immune responses, and mucus hypersecretion. Next, we evaluated the feasibility of the HNO-ALI respiratory virus model system to test the efficacy of palivizumab to prevent RSV infection. Palivizumab was administered in the basolateral compartment (circulation), while viral infection occurred in the apical ciliated cells (airways), simulating the events in infants. In our model, palivizumab effectively prevented RSV infection in a concentration-dependent manner. Thus, the HNO-ALI model can serve as an alternative to lung organoids to study respiratory viruses and test therapeutics. IMPORTANCE Preclinical models that recapitulate aspects of human airway disease are essential for the advancement of novel therapeutics and vaccines. Here, we report a versatile airway organoid model, the human nose organoid (HNO), that recapitulates the complex interactions between the host and virus. HNOs are obtained using noninvasive procedures and show divergent responses to SARS-CoV-2 and RSV infection. SARS-CoV-2 induces severe damage to cilia and the epithelium, no interferon-λ response, and minimal mucus secretion. In striking contrast, RSV induces hypersecretion of mucus and a profound interferon-λ response with ciliary damage. We also demonstrated the usefulness of our ex vivo HNO model of RSV infection to test the efficacy of palivizumab, an FDA-approved monoclonal antibody to prevent severe RSV disease in high-risk infants. Our study reports a breakthrough in both the development of a novel nose organoid model and in our understanding of the host cellular response to RSV and SARS-CoV-2 infection.

An experience of scaling and intensifying the industrial production of the Gam-COVID-Vac vector adenovirus vaccine in the limiting conditions of the pandemic

The COVID-19 pandemic has presented a global challenge to the health system. More than 200 years of world epidemiological experience since the first mass use of vaccines have convincingly shown that effective vaccines are the key tools in the fight against dangerous infectious diseases, especially epidemic and pandemic ones. In the context of a rapidly spreading pandemic of a new infectious agent, it is crucial not only to develop fundamentally new vaccines, but also to be able to quickly organise their large-scale production. In the Russian Federation, in 2020, a team of the National Research Centre for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya developed an innovative vector vaccine, Gam-COVID-Vaс, for the prevention of coronavirus disease caused by the SARS-CoV-2 virus. A number of pharmaceutical companies faced the challenge of producing the vaccine. The aim of the study was to optimise the production technology of Gam-COVID-Vac for scaling and increasing the production capacity. In the course of the work, the authors established critical quality attributes of the product, optimised analytical methods for their control, identified poorly scalable technological stages, streamlined the technological process before its transfer to production, and modified non-scalable and technologically unfeasible stages. The work resulted in the launch of industrial-scale production of active pharmaceutical ingredients for both components of Gam-COVID-Vac, which made it possible not only to meet the critical need for COVID-19 immunoprophylaxis in the Russian Federation, but also to supply this vaccine to a number of foreign countries.

Monoclonal gammopathy in COVID-19 pregnant patients

Monoclonal gammopathies (MG) are a group of disorders ranging from the benign to the malignant plasma cell dyscrasias to the lymphoproliferative disorders, typically characterized by the presence of a monoclonal component (MC) at serum protein electrophoresis (SPE). This condition has been also observed in association with a spectrum of acute and chronic inflammatory diseases, including viral infections. We selected for this study pregnant patients hospitalized from 2018 at the Department of Gynecology of the AOU Federico II of Naples (that include from March 2020 a section dedicated to pregnant patients with Sars-Cov2 infection), who presented a MC at the SPE (Capillarys 2, Sebia), at prenatal checks. Our population has involved 20 pregnant patients (average age of 35yo, from 22 to 47), 8 of which tested positive for COVID-19 by real-time reverse-transcriptase polymerase chain reaction of nasopharyngeal swabs. It should be considered that 3 patients came in the prepandemic period. The MC characterization revealed: 7 patients with IgG k ranging from 1 to 10 g/L;5 with IgG k<3 g/L;1 with IgM k 7,7 g/L;5 with IgG k and IgG lambda<2 g/L;1 with 2 IgG lambda 6,7 g/L and 2,0 g/L;1 with 2 IgA k 9,6 g/L and 1,3 g/L. At hospitalization, 2 patients already had a diagnosis of MGUS, while for the others the MC presence was an occasional finding. It should be noted that 2 COVID-19 patients underwent therapy with casirivimab and imdevimab and one non COVID-19 patient to anti-D immunoprophylaxis after having already identified the MC. For 5 patients MC was detected during the second trimester and 4 of these had Sars-Cov2 infection;in the other 15 at the end of pregnancy. We observed that in the pregnant population, where in the pre COVID-19 era in our laboratory the MGUS percentage was of 0.3/year, the incidence increased to 0.6/year since February 2020. The presence of these MGUS must be investigated over time to understand the transience of the MC linked to viral infection. Previous studies hypothesized that the presence of MC during the inflammatory phase could reflect the degree of immune system hyperactivation in patients with severe COVID-19 disease. Further studies are needed to evaluate its frequency in pregnancy, longterm evolution, and prognostic role in this clinical setting.

Recent progress in immunoprophylaxis of severe acute respiratory syndrome coronavirus 2 in children younger than 5 years

Immunoprophylaxis refers to the strategy to enhance specific immunity of the body through artificial methods, which can be divided into active immunization (mainly vaccination) and passive immunization (including maternal vaccination). Vaccination is the most cost - effective measure to prevent and control the novel coronavirus disease 2019 (COVID -19). Recently, the United States, Costa Rica and Australia have authorized use of the COVID - 19 vaccine for children down to 6 months of age. In real - world evaluation, maternal vaccination was associated with a substantial reduction in incidence of severe acute respiratory syndrome coronavirus 2 (SARS - CoV - 2) infection, the risk of COVID - 19 related hospitalization and critical illness among infants younger than 6 months of age. Coupled with these advances in young children, it is possible to achieve the whole population coverage of SARS - CoV - 2 mmune prevention. © 2022 Chinese Journal of Applied Clinical Pediatrics. All rights reserved.

Evaluation of the Effectiveness of Immunization Saint-Petersburg Population against COVID-19

Relevance. Vaccination is being replaced by the primary and most effective means of protecting the world's population from a new coronavirus infection. Aim. Evaluation of the effectiveness of COVID-19 immunization in Saint-Petersburg. Materials and methods: We retrospectively studied the epidemiological data on the cumulative incidence of COVID-19 in St. Petersburg among adults vaccinated (1,558,030 people) and unvaccinated (2,863,050 people) for period from December 01, 2020 to November 30, 2021 on 12.01.2021. We analyzed the data presented in the Federal Register of Persons with COVID-19 and the Federal Register of Those Vaccinated against COVID-19. Results. The risk of COVID-19 infection among vaccinated is statistically significantly lower than among unvaccinated RR = 0.11 (95% CI 0.109–0.110;p < 0.001). Infected COVID-19 Vaccinated patients were less likely to need for emergency care/hospitalization RR = 0.30 (95% CI 0.29–0.30;p < 0.001). Also among the vaccinated mortality was lower RR = 0.35 (95% CI 0.33–0.37;p < 0.001). Conclusion: We have established reliable preventive effectiveness of the use of domestic vaccines by reducing morbidity, the frequency of development of forms of the disease requiring inpatient treatment;reducing mortality among vaccinated and, accordingly, reducing the burden on the healthcare system of St. Petersburg. © 2022, Numikom. All rights reserved.

Monitoring System for Adverse Events Following Immunization in Russia and the World. Modern aspects and problems

Relevance. During a pandemic, the epidemiological well-being of the population of the whole world depends on the vaccination of each individual person, as cells of the immune layer. Only reliable and open information about adverse events after the use of vaccines, obtained in a timely manner in the process of continuous monitoring, can support the confidence and adherence of the population to vaccination. Aim. To assess the monitoring system for AEFI (Adverse Events Following Immunization) in the Russian Federation and other countries. Materials and methods. A descriptive epidemiological study was conducted with a review of regulatory and methodological documents, forms of federal statistical observation, information from the AIS «DRAID» (Analytical Information System «Department of registration and accounting of infectious diseases» program in Moscow, acts of investigation of post-vaccination complications, which were carried out by specialists from the branches of the Center for Hygiene and Epidemiology in Moscow, sources: eLIBRARU.ru, cyberleninka.ru, information from WHO’s websites, Internet resources for monitoring AEFIs in different countries and websites of manufacturers of COVID-19 vaccines, instructions for vaccines. Conclusion. Thus, it is almost impossible for an epidemiologist working in one of the departments that participates in the monitoring of AEFIs to conduct a full-fledged prospective and retrospective epidemiological analysis and draw unambiguous conclusions about the AEFIs based only on data from open sources and forms of state statistical observation. There is a need for interaction and exchange of information between the subjects of monitoring. © 2022, Numikom. All rights reserved.

Humoral and Cellular Immune Response to a Third Dose of SARSCoV- 2 Vaccine in Kidney Transplant Recipients on Belatacept

Purpose: Kidney transplant recipients taking belatacept (KTR-B) have poor immune response to two-dose SARS-CoV-2 vaccination. We sought to characterize the impact of an additional vaccine dose on plasma neutralizing capacity and cellular responses as compared to that of KTRs controls (KTR-C) not taking belatacept. Method(s): Within an observational cohort, we tested 26 KTR-Bs and 27 KTR-Cs for anti-spike antibody responses before and after a third SARS-CoV-2 vaccine dose (D3) using two clinical assays (Roche Elecsys anti-S Ig and EUROIMMUN anti-S1 IgG). For a subset of 5 KTR-Bs and for all KTR-Cs we used a research assay (Meso Scale Diagnostics V-Plex [MSD]) to further assess anti-spike and RBD IgG, as well as surrogate plasma neutralizing activity (% ACE2 inhibition) versus the ancestral and delta variants. For 3 KTR-Bs, post D3 T cell response was assessed via IFN-y ELISpot and deemed positive if spot forming units > 20 per million PBMC and stimulation index > 3. Result(s): KTR-Bs had significant lower clinical anti-spike seroconversion than KTR-Cs (31% vs 74%, p=0.001) after D3 despite similar demographics, clinical factors, and vaccines administered (Table 1). No KTR-B (0/5) was seropositive by MSD anti-spike or anti-RBD IgG (Figure 1). % ACE2 inhibition versus the ancestral variant was significantly lower in KTR-Bs than in KTR-Cs (Median [IQR] 5.2 [2.8, 6.5] vs 12.5 [7.7, 23.9], p<0.01);all KTR-Bs were below a level consistent with detectable neutralizing antibody. All tested KTR-Bs (3/3) had a negative ELISpot, consistent with negligible cellular response. Conclusion(s): These results suggest minimal humoral or cellular immunogenicity of additional vaccine doses for KTR-Bs and indicates the need for alternative strategies to improve vaccine response such as immunosuppression alteration or use of passive immunoprophylaxis with monoclonal anti-spike antibody to improve protection versus SARS-CoV-2.

COVID-19 Vaccinating Russian Medical Students-Challenges and Solutions: A Cross-Sectional Study.

Background: The role of preventive measures increases significantly in the absence of effective specific COVID-19 treatment. Mass population immunization and the achievement of collective immunity are of particular importance. The future development of public attitudes towards SARS-CoV-2 immunization depends significantly on medical students, as future physicians. Therefore, it seemed relevant to determine the percentage of COVID-19-vaccinated medical students and to identify the factors significantly affecting this indicator. Methods: A total of 2890 medical students from years one to six, studying at nine leading Russian medical universities, participated in an anonymous sociological survey. The study was performed in accordance with the STROBE guidelines. Results: It was found that the percentage of vaccinated Russian medical students at the beginning of the academic year 2021 was 58.8 ± 7.69%, which did not significantly differ from the vaccination coverage of the general population in the corresponding regions (54.19 ± 4.83%). Student vaccination rate was largely determined by the region-specific epidemiological situation. The level of student vaccination coverage did not depend on the gender or student residence (in a family or in a university dormitory). The group of senior students had a higher number of COVID-19 vaccine completers than the group of junior students. The lack of reliable information about COVID-19 vaccines had a pronounced negative impact on the SARS-CoV-2 immunization process. Significant information sources influencing student attitudes toward vaccination included medical professionals, medical universities, academic conferences, and manuscripts, which at that time provided the least information. Conclusion: The obtained results make it possible to develop recommendations to promote SARS-CoV-2 immunoprophylaxis among students and the general population and to increase collective immunity.

Coronavirus Infections in Animals: Risks of Direct and Reverse Zoonoses.

The publications on animal coronavirus infections that have the greatest emerging potential, as well as official data from the World Organization for Animal Health (OIE) on cases of animal infection with COVID-19, are analyzed. Like most infectious diseases common to humans, coronavirus infections were first discovered in animals. Due to the increased rate of replication and recombination activity compared to other viruses, mutations occur more often in the genome of coronaviruses, which contribute to the acquisition of new qualities in order to consolidate in the host organism. Examples of cross-species transmission are not only SARS-CoV, MERS-CoV, and SARS-CoV-2, which are dangerous to humans, but also coronaviruses of agricultural and domestic animals, between which there is a genetic relationship. There are several known cases of zoo, wild, domestic, and farm animals displaying symptoms characteristic of COVID-19 and identification of the genome of the SARS-CoV-2 virus in them. The issue of cross-species transmission of coronavirus infections, in particular the reverse zoonosis of SARS-CoV-2 from animals to humans, is widely discussed. According to the conclusions of many researchers, including OIE experts, there is no direct evidence base for infection of humans with COVID-19 from animals. However, people with suspected COVID-19 and with a confirmed diagnosis are still advised to isolate not only from people but also from animals. A number of methods for specific prevention, diagnosis, and immunization against a wide range of coronavirus infections are being developed at the All-Russia Research Institute for Animal Protection.

The attitude of young mothers to vaccination in modern conditions.

Vaccination is one of the most important preventive areas in medicine, the role of which has increased in the context of the COVID-19 pandemic. However, the territorial features of awareness and attitudes towards vaccination of young mothers have not been studied. Purpose of the study. To assess the attitude to vaccination and awareness of young mothers on the example of residents of the Smolensk region. Material and methods. In the period from September to December 2021, a survey was conducted of 200 mothers (mean age 23.5±5.1 years) living in Smolensk. The original questionnaire was used, including 7 closed and 3 open questions. The results of the survey were evaluated using a qualitative analysis. Results. The results of a qualitative study of the attitude of young mothers to vaccination showed that most mothers have a positive attitude towards the vaccination of their children and themselves in order to maintain health. At the same time, only about 50% of them vaccinate their children within the time limits set by the national vaccination calendar. 82% of young mothers pointed to medical workers as the main source of information about immunoprophylaxis. Of the total number of mothers surveyed, only 9% were not vaccinated themselves, and 11.5% of respondents categorically refused to vaccinate their children. The main reason for their refusal was the fear of post-vaccination reactions and complications, 47% of mothers do not see the need for vaccination and 24.5% believe that the harm from vaccination exceeds the risk of infection. Conclusion. The results of the study indicate the need to conduct trainings for doctors and other medical workers on motivation for immunoprophylaxis, strengthen health education among the population and conduct conversations with parents about the possible consequences of not vaccinating. (English) [ FROM AUTHOR] Вакцинация - одно из важнейших профилактических направлений в медицине, роль которого возросла в условиях пандемии COVID-19. Вместе с тем не изучены территориальные особенности информированности и отношения к вакцинопрофилактике молодых матерей. Цель исследования. Оценить отношение к вакцинопрофилактике и информированность молодых матерей на примере жителей Смоленской области. Материал и методы. В период с сентября по декабрь 2021 г. проведено анкетирование 200 матерей (средний возраст 23,5±5,1 года), проживающих в г. Смоленск. Использована оригинальная анкета, включающая 7 закрытых и 3 открытых вопроса. Результаты опроса оценивали с помощью квалитативного анализа. Результаты. Результаты квалитативного исследования отношения молодых матерей к вакцинации показали, что большинство матерей положительно относятся к вакцинации детей и себя лично для сохранения здоровья. При этом только примерно 50% из них прививают своих детей в сроки, установленные национальным календарем прививок. На медицинских работников как на основной источник информации об иммунопрофилактике указало 82% молодых матерей. Из всего числа анкетированных матерей только 9% не привиты сами и 11,5% респондентов категорически отказывались от вакцинации своих детей. Основной причиной их отказа была боязнь поствакцинальных реакций и осложнений, 47% матерей не видят необходимости в проведении вакцинации и 24,5% считают, что вред от прививок превышает риск заражения. Заключение. Результаты исследования свидетельствуют о необходимости проведения тренингов для врачей и других медицинских работников по мотивированию к иммунопрофилактике, а также усиления санитарно-просветительской работы среди населения и проведения бесед с родителями о возможных последствиях отсутствия вакцинации. (Russian) [ FROM AUTHOR] Copyright of Profilakticheskaya Meditsina is the property of Media Sphere Publishing House and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)

Post-vaccination and post-infection humoral immune response to the SARS-CoV-2 infection

Introduction. Mass vaccination of the population against SARS-CoV-2 in Russia and abroad has been going on for more than 2 years. Various types of vaccines are used for vaccination (vector vaccines, RNA vaccines, whole-virion vaccines). The first in the world was registered the Russian vector vaccine «Gam-COVID-Vac» («Sputnik V»), which is widely used in our country, as well as in many other countries of the world. An important area of research is the monitoring of the parameters of the vaccine-induced immune response their analysis in relation to the characteristics of the immune response caused by SARSCoV-2 infection/COVID-19. Such studies are important both for assessing the intensity and duration of post-vaccination immunity, and for improving strategies for immunoprophylaxis and immunotherapy of coronavirus infection. The article presents the results of a study of the humoral immune response in patients with COVID-19 and vaccinated with «Sputnik V» in the period from autumn 2020 till the present time. The aim of the work - a comparative study of the humoral immune response to SARSCoV-2 infection and vaccination against COVID-19. Material and methods. The content of antibodies against SARS-CoV-2 S- and N-proteins was studied in 449 blood serum samples of men and women (age 25-65 years). 5 groups of samples were formed: suffered from COVID-19 of mild and moderate severity, at different times after recovery (262 samples);immunized with the «Sputnik V» vaccine, at different times after injection of the 2nd component of «Sputnik V» (104 samples);suffered from COVID-19 of mild and moderate severity, and then vaccinated with «Sputnik V» (53 samples);vaccinated with «Sputnik V», and then suffered with COVID-19 (12 samples);revaccinated with the vaccine «Sputnik Light» (18 samples). Results. To assess the content of IgG antibodies to S-protein and to N-protein of SARSCoV-2 in human blood sera, an EIA diagnostic system was developed further certified by the Ministry of Health of Russian Federation. In people suffered COVID-19 in 90 % of cases the positive levels of IgG antibodies to SARS-CoV-2 S-protein persist 9 months after recovery, while the proportion of potential plasma donors and material for obtaining intravenous immunoglobulin with a high content of IgG antibodies to S-protein 1 month after the disease is 20 %. In 76 % of people vaccinated with «Sputnik V» high levels of IgG antibodies to S-protein are detected within 6 months after the course of vaccination. The content of IgG antibodies to S-protein in the blood sera of persons suffered COVID-19, and then 6 months after recovery vaccinated with the 1st component of the vaccine «Sputnik V» in 100 % of cases was high with a positivity coefficient above 8.1, regardless of the initial value, already on 7 and 21 days after injection. In persons vaccinated with «Sputnik V» and then passed COVID-19, a high content of S-specific IgG antibodies is observed in 100 % of cases. The examination of vaccinated persons who underwent revaccination with «Sputnik Light» showed a 100 % high level of antibodies against S-protein. Conclusion. The developed test system may be suitable for assessing the content of IgG antibodies to SARS-CoV-2 antigens in COVID-19 patients, vaccinated and revaccinated. The performed study demonstrated that there is a intensive post-vaccination immunity for 6 months and post-infectious immunity for 9 months.

Intranasal Lentiviral Vector-Mediated Antibody Delivery Confers Reduction of SARS-CoV-2 Infection in Elderly and Immunocompromised Mice.

Vaccines for COVID-19 are now a crucial public health need, but the degree of protection provided by conventional vaccinations for individuals with compromised immune systems is unclear. The use of viral vectors to express neutralizing monoclonal antibodies (mAbs) in the lung is an alternative approach that does not wholly depend on individuals having intact immune systems and responses. Here, we identified an anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibody, NC0321, which can efficiently neutralize a range of SARS-CoV-2 variants, including alpha, beta, delta, and eta. Both prophylactic and therapeutic NC0321 treatments effectively protected mice from SARS-CoV-2 infection. Notably, we adopted viral vector-mediated delivery of NC0321 IgG1 as an attractive approach to prevent SARS-CoV-2 infection. The NC0321 IgG1 expression in the proximal airway, expressed by a single direct in-vivo intranasal (I.N.) administration of a self-inactivating and recombinant lentiviral vector (rSIV.F/HN-NC0321), can protect young, elderly, and immunocompromised mice against mouse-adapted SARS-CoV-2 surrogate challenge. Long-term monitoring indicated that rSIV.F/HN-NC0321 mediated robust IgG expression throughout the airway of young and SCID mice, importantly, no statistical difference in the NC0321 expression between young and SCID mice was observed. A single I.N. dose of rSIV.F/HN-NC0321 30 or 180 days prior to SARS-CoV-2 challenge significantly reduced lung SARS-CoV-2 titers in an Ad5-hACE2-transduced mouse model, reconfirming that this vectored immunoprophylaxis strategy could be useful, especially for those individuals who cannot gain effective immunity from existing vaccines, and could potentially prevent clinical sequelae.

REPURPOSING OF POLIO VACCINE IN PREVENTION OF COVID-19: THINKING TOWARDS MORE OPTIONS

COVID-19 has created an unprecedented crisis worldwide in every sector. There currently is no approved drug available against this disease. The development of a vaccine is also a complex and long process that is often completed in 10-15 years. Recently, several vaccines for COVID-19 have received emergency approval for use but few experts deem that currently approved COVID-19 vaccines might provide a temporary boost to the immune system, but they are dubious for their long-term effect and safety. This article sheds light on polio vaccine as a possibility on COVID-19 prophylaxis because this vaccine was developed through a rigorous process of the various phases of development. The polio vaccine could provide another option to combat COVID-19 and if we have more options, we can fight more effectively against the pandemic. The polio vaccine is utilized globally with a highly satisfactory retort and very good immune responses. By seeing a satisfactory cross-protective immune response, the polio vaccination could be repurposed and offered against COVID-19 for an effective immuno-prophylaxis and protection. This article focusses on the repurposing of vaccines/drugs for COVID-19 and discusses the scientific rationale behind the suggestive use of the polio vaccine against COVID-19 because the polio vaccine is FDA-approved less expensive, readily available, easy to administer, and highly safe.

VACCINATION OF PATIENTS WITH DIABETES MELLITUS

Diabetes mellitus stays an important medical, economic and social problem worldwide. Infectious diseases in people with diabetes mellitus are often more severe with an increased frequency of hospitalizations and complications. The presence of chronic hyperglycemia leads to decreased immune function and an increased predisposition to infections. Infections lead to uncontrolled hyperglycemia, which worsens the course of infections, thus forming a vicious circle of violations. Mass vaccination with an emphasis on people belonging to the high-risk group reduces the number of infected and, hospitalized people, and also has clear economic advantages. However, in many countries the proportion of vaccinated remains low. Vaccine prophylaxis in Russia is regulated by a number of regulatory legal acts, of which the main one is Federal Law No. 157-FZ of September 17, 1998 (edited on July 2, 2021) "About Immunoprophylaxis of Infectious Diseases". Each country has a National Vaccination Schedule, which shows a routine vaccination schedule at a specific age against infections that are widespread and / or pose a serious threat to health and life), as well as a National Epidemic Indication Vaccination Schedule. In Russia, these documents are approved by Order of the Ministry of Health of the Russian Federation of March 21, 2014 N 125. "About the approval of the national calendar of preventive vaccinations and the calendar of preventive vaccinations for epidemic indications." This article discusses vaccination against the most socially significant infections associated with a high worldwide prevalence and increased risk among people with diabetes.